{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"萌喵读文献-肿瘤学","title":"今日肿瘤学最高分文献 - 2025-01-30","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/1b976bc6\"></iframe>","width":"100%","height":180,"duration":100,"description":"欢迎收听今日医学焦点！一项突破性研究关注于tarlatamab，这是一种针对小细胞肺癌患者的最新双特异性T细胞引导免疫疗法。DeLLphi-301试验显示，每两周一次的10mg剂量治疗能够带来持久反应和生存益处。然而，常见的副作用包括细胞因子释放综合征、发热、食欲下降等，通常在第一或第二次给药后出现，并可通过支持性护理管理。作为首款获批治疗小细胞肺癌的T细胞引导疗法，了解并管理这些副作用至关重要。下一期节目，我们将深入探讨这些发现及其对患者护理的影响。不要错过！","thumbnail_url":"https://img.transistorcdn.com/3WX36CzvFOrNjlF7WfWjzS4HdcMIMmzMs2bmPS-ejLU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83NDNm/MjQ1N2E5NjhjMzVj/NjM0ZTA3YzY2NDE2/ZmIyMi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}